In a recent validation study, researchers involved in developing Biotheranostics' Breast Cancer Index test have found that the BCI outperformed Genomic Health's Oncotype DX in predicting longer-term recurrence risk, as well as early recurrence risk in a subgroup of HER2-negative
In support of expanded utility for its Oncotype DX test in guiding cancer therapy decision-making, Genomic Health announced new data this week demonstrating that the test can help predict patients' risk of loco-regional recurrence after receiving chemotherapy and hormonal therapy
Ahead of a planned launch of its prostate cancer prognostic test, Decipher, later this year, GenomeDx presented data from four studies at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium last week.
Drug testing lab Dominion Diagnostics and nutrigenomics firm LifeGen announced an agreement last month giving Dominion exclusive licensing rights to a biomarker signature LifeGen has developed to predict a patient's risk for addiction.
Canada's Prevention of Organ Failure Centre of Excellence has granted HTG Molecular Diagnostics exclusive rights to commercialize a risk stratification test the center has been developing to better personalize treatment for chronic obstructive pulmonary disease.
Canada's Prevention of Organ Failure Centre of Excellence in Vancouver is using C$1.5 million (US$1.5 million) in funding from Genome British Columbia and other groups to develop a molecular test intended to personalize treatment for chronic obstructive pulmonary disease.
